Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 2/20 | 0.40 |
| ▸ | CNR2 | P34972 | 2/20 | 0.40 |
| ▸ | RXRA | P19793 | 1/20 | 0.38 |
| ▸ | RXRB | P28702 | 1/20 | 0.38 |
| ▸ | RXRG | P48443 | 1/20 | 0.38 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.36 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.36 |
| ▸ | ATR | Q13535 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | ELOVL1 | Q9BW60 | 1/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.34 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.34 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27037194 | 0.81 | CNR1 (0.40) | CNR1CNR2RXRARXRBRXRG | |
| SCHEMBL21187503 | 0.81 | CYP4F2 (0.43) | CNR1CNR2RXRARXRBRXRG | |
| SCHEMBL25407969 | 0.79 | RET (0.43) | RXRARXRBRXRGCYP4F2CYP4A11 | |
| SCHEMBL3433705 | 0.79 | CNR1 (0.38) | CNR1CNR2RXRARXRBRXRG | |
| SCHEMBL21185042 | 0.79 | RET (0.39) | CNR1CNR2RXRARXRBRXRG | |
| SCHEMBL3037205 | 0.78 | CYP4F2 (0.42) | RXRARXRBRXRGCYP4F2CYP4A11 | |
| SCHEMBL3623334 | 0.77 | RXRA (0.40) | CNR1CNR2RXRARXRBRXRG | |
| SCHEMBL3039870 | 0.74 | CYP4F2 (0.37) | RXRARXRBRXRGCYP4F2CYP4A11 | |
| SCHEMBL2215449 | 0.73 | CYP4F2 (0.47) | RXRARXRBRXRGCYP4F2CYP4A11 | |
| SCHEMBL2593255 | 0.72 | CNR1 (0.35) | CNR1CNR2RXRARXRBRXRG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348439-A1 | INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | NIDO BIOSCIENCES INC (US) | 2023-11-02 | — | — | US | disclosed |
| EP-4182320-A1 | INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | Nido Biosciences, Inc. (US) | 2023-05-24 | — | — | EP | disclosed |
| WO-2022020342-A1 | INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | NIDO BIOSCIENCES, INC. (US) | 2022-01-27 | — | — | WO | disclosed |
| EP-2210880-B1 | Benzoxazinone derivatives | MSD KK (JP) | 2015-08-26 | — | — | EP | disclosed |
| US-8314094-B2 | Benzoxazinone derivative | MSD K.K (JP) | 2012-11-20 | — | — | US | disclosed |
| US-20100210636-A1 | BENZOXAZINONE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. | 2010-08-19 | — | — | US | disclosed |
| EP-2210880-A1 | BENZOXAZINONE DERIVATIVE | Banyu Pharmaceutical Co., Ltd. (JP) | 2010-07-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348439-A1 | INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | AR, FSHR, NR5A1 | CNR1 165/4885CNR2 238/4885RXRA 692/4885 |
| US-20100210636-A1 | BENZOXAZINONE DERIVATIVE | HAX1, CYP4X1, CYP19A1 | CNR1 301/4885CNR2 562/4885RXRA 352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.